Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
1.
PLoS One ; 11(5): e0156071, 2016.
Article in English | MEDLINE | ID: mdl-27244221

ABSTRACT

INTRODUCTION: Feeding strategies are critical for healthy growth in preterm infants. Bile salt-stimulated lipase (BSSL), present in human milk, is important for fat digestion and absorption but is inactivated during pasteurization and absent in formula. This study evaluated if recombinant human BSSL (rhBSSL) improves growth in preterm infants when added to formula or pasteurized breast milk. PATIENTS AND METHODS: LAIF (Lipase Added to Infant Feeding) was a randomized, double-blind, placebo-controlled phase 3 study in infants born before 32 weeks of gestation. The primary efficacy variable was growth velocity (g/kg/day) during 4 weeks intervention. Follow-up visits were at 3 and 12 months. The study was performed at 54 centers in 10 European countries. RESULTS: In total 415 patients were randomized (rhBSSL n = 207, placebo n = 208), 410 patients were analyzed (rhBSSL n = 206, placebo n = 204) and 365 patients were followed until 12 months. Overall, there was no significantly improved growth velocity during rhBSSL treatment compared to placebo (16.77 vs. 16.56 g/kg/day, estimated difference 0.21 g/kg/day, 95% CI [-0.40; 0.83]), nor were secondary endpoints met. However, in a predefined subgroup, small for gestational age infants, there was a significant effect on growth in favor of rhBSSL during treatment. The incidence of adverse events was higher in the rhBSSL group during treatment. CONCLUSIONS: Although this study did not meet its primary endpoint, except in a subgroup of infants small for gestational age, and there was an imbalance in short-term safety, these data provide insights in nutrition, growth and development in preterm infants. TRIAL REGISTRATION: ClinicalTrials.gov NCT01413581.


Subject(s)
Dietary Supplements/adverse effects , Enteral Nutrition/methods , Infant, Premature/growth & development , Recombinant Proteins/pharmacology , Sterol Esterase/pharmacology , Weight Gain/drug effects , Bottle Feeding/methods , Double-Blind Method , Female , Gestational Age , Humans , Infant , Infant Formula/chemistry , Infant, Newborn , Male , Milk, Human/chemistry , Pasteurization , Placebos , Recombinant Proteins/genetics , Sterol Esterase/adverse effects , Sterol Esterase/genetics
2.
J Pediatr Gastroenterol Nutr ; 59(1): 61-9, 2014 Jul.
Article in English | MEDLINE | ID: mdl-25222806

ABSTRACT

OBJECTIVES: Preterm infants often experience suboptimal growth, which can affect organ development. The aim of this study was to improve growth by treatment with bile salt-stimulated lipase (BSSL), naturally present in breast milk, but lost after pasteurization, and absent in formula. METHODS: Two clinical trials were performed with a predefined analysis of combined data to investigate the effects of recombinant human BSSL (rhBSSL) treatment on growth velocity and fat absorption in preterm infants. The studies were randomized and double-blinded comparing 7-day treatment with rhBSSL and placebo, administered in pasteurized breast milk or formula, using a crossover design. RESULTS: Sixty-three infants were evaluated for safety. At randomization, the mean (standard deviation) weight was 1467 (193) g and mean postmenstrual age was 32.6 (0.5) weeks. Sixty and 46 infants were evaluated for growth velocity and fat absorption, respectively. rhBSSL treatment significantly improved mean growth velocity by 2.93 g · kg · day (P<0.001) compared with placebo (mean 16.86 vs 13.93 g · kg · day) and significantly decreased the risk of suboptimal growth (<15 g · kg · day) (30% vs 52%, P=0.004). rhBSSL significantly increased absorption of the long-chain polyunsaturated fatty acids, docosahexaenoic acid, and arachidonic acid by 5.76% (P=0.013) and 8.55% (P=0.001), respectively, but had no significant effect on total fat absorption. The adverse-event profile was similar to placebo. CONCLUSIONS: In preterm infants fed pasteurized breast milk or formula, 1 week of treatment with rhBSSL was well tolerated and significantly improved growth and long-chain polyunsaturated fatty acid absorption compared to placebo. This publication presents the first data regarding the use of rhBSSL in preterms and the results have led to further clinical studies.


Subject(s)
Infant, Premature/growth & development , Infant, Very Low Birth Weight/growth & development , Intestinal Absorption/drug effects , Sterol Esterase/therapeutic use , Arachidonic Acid/pharmacokinetics , Child Development , Cross-Over Studies , Docosahexaenoic Acids/pharmacokinetics , Double-Blind Method , Female , Humans , Infant , Infant Formula/administration & dosage , Infant, Newborn , Male , Milk, Human/enzymology , Pasteurization , Recombinant Proteins/therapeutic use , Sterol Esterase/adverse effects
3.
Hum Psychopharmacol ; 22(5): 315-25, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17542047

ABSTRACT

AIM: This analysis evaluated the tolerability profile of quetiapine using data from all comparative controlled studies in patients with schizophrenia or related disorders in the AstraZeneca clinical trials database, focusing on extrapyramidal symptoms (EPS). METHODS: Adverse event (AE) data from randomised, double-blind, controlled studies in the AstraZeneca clinical trials database were pooled, allowing comparison of quetiapine (mean daily doses 357-496 mg/day) with placebo, haloperidol (10.4 mg/day), risperidone (5.5 mg/day) or chlorpromazine (552 mg/day). Incidence of EPS-related AEs in relation to quetiapine dose was also analysed using a subset of data from fixed-dose studies. RESULTS: Data from 4956 patients were analysed. Quetiapine was well tolerated, and did not increase EPS-related AEs when compared with placebo (9.6 vs. 10.6%, respectively). The incidence of EPS-related AEs with quetiapine was consistent across the dose range (4.2-13.2% vs. 11.1% with placebo). Patients receiving haloperidol, risperidone and chlorpromazine experienced significantly higher levels of EPS-related AEs than those on quetiapine. The most common quetiapine- associated AEs, with significantly higher incidence than placebo, were sedation, somnolence and orthostatic hypotension. CONCLUSION: Quetiapine is generally well tolerated in patients with schizophrenia or related disorders, with placebo-level EPS-related AEs. Quetiapine has a more favourable EPS profile than haloperidol, chlorpromazine or risperidone.


Subject(s)
Antipsychotic Agents/adverse effects , Basal Ganglia Diseases/chemically induced , Dibenzothiazepines/adverse effects , Schizophrenia/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Antipsychotic Agents/therapeutic use , Basal Ganglia Diseases/epidemiology , Chlorpromazine/adverse effects , Dibenzothiazepines/therapeutic use , Female , Haloperidol/adverse effects , Humans , Incidence , Male , Middle Aged , Quetiapine Fumarate , Randomized Controlled Trials as Topic , Risperidone/adverse effects
4.
Int J Psychiatry Clin Pract ; 11(1): 61-72, 2007.
Article in English | MEDLINE | ID: mdl-24941277

ABSTRACT

We have considered published work and clinical experience focusing on the atypical antipsychotic quetiapine in order to form a consensus on the most appropriate treatment strategies for hospitalised patients with acute schizophrenia or bipolar disorder. It is important to consider the specific treatment needs of these patients and these are discussed in the context of current treatment guidelines. We will review the efficacy and tolerability of atypical antipsychotics versus conventional antipsychotics and/or benzodiazepines as a first-line treatment, and examine the suitability of oral versus intramuscular formulations in the acute setting. The potentially beneficial properties of specific atypical agents are also considered. Appropriate dosing is particularly important in acutely ill patients as it can help achieve rapid improvement. We will discuss emerging data which show that rapid initiation of quetiapine in patients with acute psychosis or mania is not only as effective as standard initiation, but is also well tolerated. This may be important for treatment in the long term as a positive initial treatment experience can determine patient compliance and treatment adherence. In conclusion, this review recommends that oral atypical antipsychotics should be a first-choice medication for acutely ill cooperative patients in the hospital setting.

5.
Int J Geriatr Psychiatry ; 19(12): 1123-30, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15526307

ABSTRACT

BACKGROUND: The objectives of the study were to compare efficacy and tolerability of venlafaxine ER 75-150 mg/day with that of citalopram 10-20 mg/day in elderly patients with major depression according to DSM-IV criteria. METHODS: A randomised, double-blind, parallel group 6-month study. Efficacy was assessed by MADRS, CGI Global Improvement, CGI Severity of Illness and GDS-20 scores and safety by physical examinations, vital signs, adverse events and UKU side effect rating. Plasma levels of venlafaxine, its major metabolite O-desmethylvenlafaxine and citalopram were followed. RESULTS: One hundred and fifty-one male and female patients (64-89 years) were enrolled and 118 patients completed the study. Comparable improvements in MADRS, CGI Severity of Illness, CGI Global Improvement and GDS-20 were observed during venlafaxine and citalopram treatment. The MADRS remission rate was 19% for venlafaxine and 23% for citalopram. Side effects were common during both treatments but differed in tremor being more common during citalopram and nausea/vomiting during venlafaxine treatment. There were no clinically significant changes in blood pressure or body weight. CONCLUSION: The observed benefits of venlafaxine treatment in elderly patients with major depression were similar to those observed in younger adults as were reported adverse events and side effects. Treatment with venlafaxine ER was well tolerated and induced beneficial effects of similar magnitude as those of citalopram.


Subject(s)
Antidepressive Agents/therapeutic use , Citalopram/therapeutic use , Cyclohexanols/therapeutic use , Depressive Disorder, Major/drug therapy , Aged , Aged, 80 and over , Antidepressive Agents/adverse effects , Antidepressive Agents/blood , Antidepressive Agents, Second-Generation/adverse effects , Antidepressive Agents, Second-Generation/blood , Antidepressive Agents, Second-Generation/therapeutic use , Body Weight/physiology , Citalopram/adverse effects , Citalopram/blood , Cyclohexanols/adverse effects , Cyclohexanols/blood , Depressive Disorder, Major/blood , Desvenlafaxine Succinate , Double-Blind Method , Female , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , Severity of Illness Index , Venlafaxine Hydrochloride
SELECTION OF CITATIONS
SEARCH DETAIL
...